All > Paid Studies Houston > Gout

Tigulixostat 200mg for High Uric Acid

Phase-Based Progress Estimates
2
Effectiveness
3
Safety
High Uric Acid+3 MoreTigulixostat - Drug
Eligibility
18 - 85
All Sexes
What conditions do you have?
Select

Study Summary

The aim of this 6-month randomized multi-regional double-blind parallel group placebo-controlled phase 3 study is to assess the efficacy and safety of three different doses of Tigulixostat in gout patients with hyperuricemia.

Eligible Conditions
  • Gouty Tophi
  • High Uric Acid
  • Gout Flare
  • Gout

Treatment Effectiveness

Effectiveness Progress

2 of 3
This is further along than 85% of similar trials

Similar Trials

1
HEX
1
Adenosine A2B Receptor Antagonist PBF-1129
1
Shockwave Treatment

Study Objectives

1 Primary · 3 Secondary · Reporting Duration: Up to Month 6

Up to Month 6
Incidence rate of adverse event
The proportion of subjects reporting a gout flare up to each visit.
The proportion of subjects with sUA levels <5.0 mg/dL sustained at months 4, 5, and 6
The proportion of subjects with sUA levels <6.0 mg/dL sustained at months 4, 5, and 6

Trial Safety

Safety Progress

3 of 3
This is further along than 85% of similar trials

Similar Trials

1
HEX
1
Adenosine A2B Receptor Antagonist PBF-1129
1
Shockwave Treatment

Trial Design

4 Treatment Groups

Tigulixostat 200mg
1 of 4
Tigulixostat 300mg
1 of 4
Tigulixostat 100mg
1 of 4
Placebo
1 of 4

Experimental Treatment

Non-Treatment Group

350 Total Participants · 4 Treatment Groups

Primary Treatment: Tigulixostat 200mg · Has Placebo Group · Phase 3

Tigulixostat 200mg
Drug
Experimental Group · 1 Intervention: Tigulixostat · Intervention Types: Drug
Tigulixostat 300mg
Drug
Experimental Group · 1 Intervention: Tigulixostat · Intervention Types: Drug
Tigulixostat 100mg
Drug
Experimental Group · 1 Intervention: Tigulixostat · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Placebo · Intervention Types: Drug

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: up to month 6

Who is running the clinical trial?

LG ChemLead Sponsor
55 Previous Clinical Trials
30,134 Total Patients Enrolled
Jisoo Lee, MDStudy DirectorLG Chem
2 Previous Clinical Trials
10,542 Total Patients Enrolled

Eligibility Criteria

Age 18 - 85 · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
Subjects who are currently on urate-lowering therapies (ULT) with an sUA level ≥6.0 mg/dL at screening (Visit 1); or subjects who are currently not on ULT with an sUA level ≥7.
You are male or female, between the ages of 18 and 85 years, inclusive.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top